FLASH NEWS LIVE

BioAge Labs Touts Oral NLRP3 Inhibitor BGE-102 Data, Eyes CV Study and Retinal Expansion

BioAge Labs Touts Oral NLRP3 Inhibitor BGE-102 Data, Eyes CV Study and Retinal Expansion

BioAge Labs (NASDAQ:BIOA) outlined its strategy and near-term clinical plans at Oppenheimer’s 36th Annual Life Science Conference, emphasizing its focus on using human aging biology to develop therapies for metabolic disease. Co-founder and CEO Kristen Fortney was joined by team members BJ Sullivan and Dov Goldstein to discuss the company’s discovery platform, lead clinical program [...]

Read Full Article →

📱 Tip: Tap the 🔗 Share icon in Safari and choose Add to Home Screen to install World Trade Factory.
Instagram Meta X LinkedIn Whatsapp